Compare · BTI vs MDWD
BTI vs MDWD
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $125.30B, about 794.9x MDWD ($157.6M).
- BTI has been more active in the news (6 items in the past 4 weeks vs 1 for MDWD).
- BTI has more recent analyst coverage (15 ratings vs 8 for MDWD).
- Company
- British American Tobacco Industries p.l.c.
- MediWound Ltd.
- Price
- -
- -
- Market cap
- $125.30B
- $157.6M
- 1M return
- -
- -11.09%
- 1Y return
- -
- -36.61%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- 2014
- News (4w)
- 6
- 1
- Recent ratings
- 15
- 8
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 25-NSE filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest MDWD
- MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
- Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
- Director Rubinstein Samuel sold $6,678 worth of Ordinary Shares (525 units at $12.72) and bought $6,626 worth of Ordinary Shares (525 units at $12.62) (SEC Form 4)
- MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- COO & Chief Commercial Officer Hess Shmuel sold $75,394 worth of Ordinary Shares (5,823 units at $12.95), closing all direct ownership in the company (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- MediWound to Report Second Quarter 2026 Financial Results
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)